Disciplined amid Disruption

GMO’s Structured Products team explores how high quality structured credit can improve carry, reduce spread risk, and strengthen downside protection when spreads are tight.

For investors, the real opportunity in investing in AI lies in distinguishing between companies with durable competitive advantages and those exposed to the boom-and-bust cycle.

In this year-end letter, Doug Francis and Cole Weppner discuss Event-Driven Strategy results for 2025 and their outlook for 2026.

In this year-end letter, Ben Inker and George Sakoulis discuss Equity Dislocation’s results in 2025 and their outlook for 2026.

GMO's 7-Year Asset Class Forecast as of January 31, 2026.

In this year-end letter, the Focused Equity team discusses Quality Strategy results for 2025 and their outlook for 2026.

In GMO’s latest Quarterly Valuation Update, local currency rates and FX screen very cheap, while hard currency credit is rich.

Jeremy Grantham and Edward Chancellor examine today’s AI boom through market history, valuation, and past manias.

GMO's 7-Year Asset Class Forecast as of December 31, 2025.

In this webcast, GMO’s Tom Hancock, Ben Inker, Catherine LeGraw, John Thorndike, and Tina Vandersteel discussed their top market predictions for 2026 and ways investors can capitalize on these opportunities.

Recent underperformance across the Healthcare sector has set the stage for a compelling long-term opportunity, particularly among higher quality companies.

With more than 30% of U.S. market capitalization now trading above 10x sales, today’s market reflects more than optimism—it reflects risk.